FGF23 and myeloid sarcoma: In male MS patients, however, FGF23 correlated positively with total (r 0.50, p < 0.01), free (r 0.43, p = 0.02), and bioavailable 25(OH)D (r 0.43, p = 0.02); free (r 0.43, p 0.02) and bioavailable 1.25(OH)2D (r 0.43, p 0.02); and 24.25(OH)2D (r 0.46, p = 0.01), respectively.